As your partner through the entire inflammation research process, we provide solutions and help scientists in their quest to grasp the complex biological processes of inflammation and pursue effective therapeutic targets. We can quickly and expertly assist with all stages of the drug development process – from the earliest stages of discovery through regulatory approval, including GLP toxicology and transfer of relevant biomarkers into clinical studies.
Inflammatory disease encompasses a wide array of conditions characterized by a chronic inflammatory response. While many of these are autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease (IBD), allergy, asthma), some types of chronic pain, such as nociceptive pain, are also caused by a prolonged inflammatory response.
Effective inflammatory disease drug discovery requires a thorough understanding of not only the extensive pathways involved in immune response, but also the mechanisms that activate and regulate those pathways. Our scientists have gained an understanding of these complex processes through multiple successful small molecule programs targeting inflammatory disease indications that have resulted in being named as co-inventors on over 130 patents related to inflammatory and respiratory diseases, and delivered over 40 compounds to our partners within these disease areas that have been progressed to a preclinical safety assessment program (or beyond). This proven track-record of innovation, powered by a broad array of disease-relevant in vitro and in vivo models of inflammation and translational biomarkers, can make the difference in advancing inflammatory disease drug discovery programs.
- Inflammation in vivo pharmacology studies
- Chronic joint pain model
- Inflammatory pain model
- LPS-induced uveitis model
- Small molecule drug discovery
With decades of experience in the field, Charles River advises on selecting the appropriate biomarker, analytical methodology, pathology service, and toxicology endpoint to best predict an inflammatory response.
Safety Assessment Services
We offer full-service support across the entire drug discovery and development continuum, including many products and services not specific to therapeutic area or indication.
Serving the needs of both small and large molecule developers, we offer a broad range of standard and specialized laboratory services to complement and enhance drug development programs, from discovery through safety and clinical trials. From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services that comply with worldwide regulatory restrictions for the preclinical development of pharmaceuticals.
We provide a comprehensive range of testing programs and equipment to support pharmaceutical development. Our biologics testing solutions and portfolio of microbial quality control systems and services help clients ensure the safety, quality and compliance of their products. We support large molecule manufacturing from early preclinical formulation development through clinical and commercial manufacturing and release.
Exceptional support of the entire drug discovery and development process is a Charles River hallmark. As a customer-focused organization committed to advancing science and helping clients reach their goals, we continually strive to develop solutions that extend our support of their efforts. Because our industry-seasoned professionals have followed the same journey as our clients, we can provide insight into the bigger picture, advice on best practices, skilled staff to extend resources and targeted training to meet the unique challenges they face along the way.